| Structure of the Bacillus subtilis quorum-sensing peptide pheromone ComX M Okada, I Sato, SJ Cho, H Iwata, T Nishio, D Dubnau, Y Sakagami Nature chemical biology 1 (1), 23-24, 2005 | 205 | 2005 |
| Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors S Sogabe, Y Kawakita, S Igaki, H Iwata, H Miki, DR Cary, T Takagi, ... ACS medicinal chemistry letters 4 (2), 201-205, 2013 | 139 | 2013 |
| A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells M Wakita, A Takahashi, O Sano, TM Loo, Y Imai, M Narukawa, H Iwata, ... Nature communications 11 (1), 1935, 2020 | 138 | 2020 |
| Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: Novel VEGFR2 kinase inhibitors binding to inactive kinase … Y Oguro, N Miyamoto, K Okada, T Takagi, H Iwata, Y Awazu, H Miki, ... Bioorganic & medicinal chemistry 18 (20), 7260-7273, 2010 | 113 | 2010 |
| Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a … N Miyamoto, N Sakai, T Hirayama, K Miwa, Y Oguro, H Oki, K Okada, ... Bioorganic & medicinal chemistry 21 (8), 2333-2345, 2013 | 74 | 2013 |
| Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors Y Kawakita, M Seto, T Ohashi, T Tamura, T Yusa, H Miki, H Iwata, ... Bioorganic & medicinal chemistry 21 (8), 2250-2261, 2013 | 69 | 2013 |
| Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase … S Matsumoto, N Miyamoto, T Hirayama, H Oki, K Okada, M Tawada, ... Bioorganic & medicinal chemistry 21 (24), 7686-7698, 2013 | 68 | 2013 |
| Structure-based discovery of cellular-active allosteric inhibitors of FAK N Tomita, Y Hayashi, S Suzuki, Y Oomori, Y Aramaki, Y Matsushita, ... Bioorganic & medicinal chemistry letters 23 (6), 1779-1785, 2013 | 60 | 2013 |
| Vacuolin‐1 inhibits autophagy by impairing lysosomal maturation via PIK fyve inhibition O Sano, K Kazetani, M Funata, Y Fukuda, J Matsui, H Iwata FEBS letters 590 (11), 1576-1585, 2016 | 52 | 2016 |
| Discovery and characterization of novel allosteric FAK inhibitors M Iwatani, H Iwata, A Okabe, RJ Skene, N Tomita, Y Hayashi, Y Aramaki, ... European Journal of Medicinal Chemistry 61, 49-60, 2013 | 52 | 2013 |
| Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: Discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics Y Oguro, DR Cary, N Miyamoto, M Tawada, H Iwata, H Miki, A Hori, ... Bioorganic & medicinal chemistry 21 (15), 4714-4729, 2013 | 50 | 2013 |
| Design and Synthesis of Pyrrolo[3,2-d]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors … Y Kawakita, H Banno, T Ohashi, T Tamura, T Yusa, A Nakayama, H Miki, ... Journal of Medicinal Chemistry 55 (8), 3975-3991, 2012 | 42 | 2012 |
| Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism H Iwata, S Imamura, A Hori, MS Hixon, H Kimura, H Miki Biochemistry 50 (5), 738-751, 2011 | 42 | 2011 |
| A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities Y Awazu, K Nakamura, A Mizutani, Y Kakoi, H Iwata, S Yamasaki, ... Molecular cancer therapeutics 12 (6), 913-924, 2013 | 30 | 2013 |
| A back-to-front fragment-based drug design search strategy targeting the DFG-out pocket of protein tyrosine kinases H Iwata, H Oki, K Okada, T Takagi, M Tawada, Y Miyazaki, S Imamura, ... ACS medicinal chemistry letters 3 (4), 342-346, 2012 | 30 | 2012 |
| Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors N Miyamoto, Y Oguro, T Takagi, H Iwata, H Miki, A Hori, S Imamura Bioorganic & medicinal chemistry 20 (24), 7051-7058, 2012 | 29 | 2012 |
| Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2 H Iwata, S Imamura, A Hori, MS Hixon, H Kimura, H Miki Bioorganic & medicinal chemistry 19 (18), 5342-5351, 2011 | 26 | 2011 |
| Feedback activation of AMPK-mediated autophagy acceleration is a key resistance mechanism against SCD1 inhibitor-induced cell growth inhibition A Ono, O Sano, K Kazetani, T Muraki, K Imamura, H Sumi, J Matsui, ... PLoS One 12 (7), e0181243, 2017 | 24 | 2017 |
| Anti‐angiogenic and anti‐tumor effects of TAK‐593, a potent and selective inhibitor of vascular endothelial growth factor and platelet‐derived growth factor receptor tyrosine … Y Awazu, A Mizutani, Y Nagase, S Tsuchiya, K Nakamura, Y Kakoi, ... Cancer science 104 (4), 486-494, 2013 | 21 | 2013 |
| A novel pyrrolo[3, 2‐d]pyrimidine derivative, as a vascular endothelial growth factor receptor and platelet‐derived growth factor receptor tyrosine kinase inhibitor … Y Awazu, A Mizutani, Y Nagase, H Iwata, Y Oguro, H Miki, S Imamura, ... Cancer science 103 (5), 939-944, 2012 | 21 | 2012 |
Mark HixonJohnson & JohnsonVerified email at its.jnj.com
Mark HixonJohnson & JohnsonVerified email at its.jnj.com